Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery.

ABSTRACT: Small interfering RNA (siRNA)-mediated mRNA degradation approach have imparted its eminence against several difficult-to-treat genetic disorders and other allied diseases. Viral outbreaks and resulting pandemics have repeatedly threatened public health and questioned human preparedness at the forefront of drug design and biomedical readiness. During the recent pandemic caused by the SARS-CoV-2, mRNA-based vaccination strategies have paved the way for a new era of RNA therapeutics. RNA Interference (RNAi) based approach using small interfering RNA may complement clinical management of the COVID-19. RNA Interference approach will primarily work by restricting the synthesis of the proteins required for viral replication, thereby hampering viral cellular entry and trafficking by targeting host

SUBMITTER: Fopase R 

PROVIDER: S-EPMC9939533 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature